NYSE:LLY
Eli Lilly & Co. (LLY)
Financials 
Technical Analysis 
Jun 4, 2026, 12:00 amThis summary was created by AI, based on 28 opinions in the last 12 months.
Eli Lilly & Co. (LLY) is regarded as a leading contender in the GLP-1 (glucagon-like peptide-1) drug market, primarily for weight loss and related conditions. Experts highlight its significant pipeline of drugs, including recent acquisitions like Centessa, which broaden its therapeutic reach. While LLY has faced some downward pressure due to competition, particularly from Novo Nordisk (NVO), many affirm that LLY’s diversification and superior execution position it well for future growth. Some analysts express caution over current valuation metrics, indicating it may be overpriced relative to peers, but long-term growth prospects remain robust, particularly with the anticipated oral version of its weight loss drugs. Overall, LLY is viewed as a robust growth stock with substantial potential in the healthcare sector.
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
